HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank Moosig Selected Research

Churg-Strauss Syndrome (Allergic Angiitis)

1/2022Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
5/2021[Cortisone-free rheumatology-Vasculitides].
6/2020International Consensus on ANCA Testing in Eosinophilic Granulomatosis with Polyangiitis.
11/2019Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status.
1/2019Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
1/2017Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
8/2014Current and emerging techniques for ANCA detection in vasculitis.
1/2014Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): evolutions in classification, etiopathogenesis, assessment and management.
4/2013L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
1/2012Extended follow-up after stopping mepolizumab in relapsing/refractory Churg-Strauss syndrome.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank Moosig Research Topics

Disease

18Churg-Strauss Syndrome (Allergic Angiitis)
01/2022 - 06/2008
16Vasculitis (Vasculitides)
05/2022 - 01/2009
10Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
05/2022 - 06/2008
10Granulomatosis with Polyangiitis (Wegener's Granulomatosis)
05/2022 - 05/2002
5Microscopic Polyangiitis
05/2022 - 06/2008
4Rheumatoid Arthritis
09/2022 - 03/2009
3Giant Cell Arteritis (Horton Disease)
05/2021 - 01/2014
3Infections
03/2021 - 01/2009
3Asthma (Bronchial Asthma)
06/2020 - 11/2009
3Systemic Lupus Erythematosus (Libman-Sacks Disease)
07/2011 - 10/2006
3Systemic Vasculitis
11/2010 - 06/2008
2Pain (Aches)
09/2022 - 12/2007
2Disease Progression
12/2016 - 06/2013
2Eosinophilia
11/2010 - 11/2009
2Granuloma
06/2008 - 05/2002
1Renal Insufficiency (Renal Failure)
09/2022
1Sleep Initiation and Maintenance Disorders (Insomnia)
09/2022
1Coronary Disease (Coronary Heart Disease)
09/2022
1Fatigue
09/2022
1Glomerulonephritis
06/2020
1Hemorrhage
06/2020
1Kidney Diseases (Kidney Disease)
06/2020
1Skin Manifestations
06/2020
1Purpura
06/2020
1Polyneuropathies (Polyneuropathy)
06/2020
1Sarcoidosis (Schaumann Disease)
03/2020
1Autoimmune Diseases (Autoimmune Disease)
11/2019
1Polymyalgia Rheumatica (Rhizomelic Pseudopolyarthritis)
03/2017
1Pulmonary Fibrosis (Fibrosing Alveolitis)
12/2016
1Pathologic Constriction (Stenosis)
12/2016
1Leukopenia
03/2016
1Erdheim-Chester Disease
10/2015
1Disease Susceptibility (Diathesis)
04/2015
1Genetic Predisposition to Disease (Genetic Predisposition)
10/2011
1Multiple Myeloma
07/2011
1Hypereosinophilic Syndrome (Loeffler Endocarditis)
11/2010
1Immune System Diseases (Immune Disorders)
05/2010
1Inflammation (Inflammations)
11/2009
1Pneumonia (Pneumonitis)
01/2009
1Hyperalgesia
12/2007
1Neoplasms (Cancer)
12/2007

Drug/Important Bio-Agent (IBA)

13Antineutrophil Cytoplasmic Antibodies (ANCA)IBA
05/2022 - 06/2008
5GlucocorticoidsIBA
09/2022 - 10/2006
5mepolizumabIBA
01/2022 - 01/2012
5AntibodiesIBA
06/2020 - 06/2008
4EnzymesIBA
03/2020 - 11/2010
4Myeloblastin (Proteinase 3)IBA
12/2016 - 06/2008
3tocilizumab (atlizumab)FDA Link
09/2022 - 03/2021
3ImmunosorbentsIBA
03/2020 - 11/2010
3CytokinesIBA
03/2017 - 05/2002
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
12/2016 - 01/2009
2Rituximab (Mabthera)FDA Link
05/2022 - 12/2016
2Prednisolone (Predate)FDA LinkGeneric
01/2022 - 01/2017
2Prednisone (Sone)FDA LinkGeneric
01/2022 - 01/2017
2avacopanIBA
05/2021 - 01/2021
2AntigensIBA
06/2020 - 01/2017
2Immunoglobulins (Immunoglobulin)IBA
03/2020 - 03/2017
2Proteins (Proteins, Gene)FDA Link
03/2020 - 03/2009
2AutoantibodiesIBA
03/2020 - 11/2010
2Peroxidase (Myeloperoxidase)IBA
12/2016 - 06/2008
1ametantrone (HAQ)IBA
09/2022
1Prostaglandins AIBA
05/2022
1CortisoneFDA Link
05/2021
1negative elongation factorIBA
03/2020
1HLA-DQ Antigens (HLA-DQ)IBA
11/2019
1Interleukin-4 (Interleukin 4)IBA
03/2017
1Interleukin-10 (Interleukin 10)IBA
03/2017
1Immunoglobulin G (IgG)IBA
03/2017
1Biomarkers (Surrogate Marker)IBA
03/2017
1Monoclonal AntibodiesIBA
01/2017
1Cytochrome P-450 CYP2C19IBA
03/2016
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
03/2016
1ProdrugsIBA
03/2016
1Cytochrome P-450 CYP2C9IBA
03/2016
1canakinumabFDA Link
10/2015
1Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
10/2015
1VemurafenibIBA
10/2015
1Amino AcidsFDA Link
04/2015
1Interleukin-33IBA
01/2014
1Chemokine CCL26IBA
10/2011
1Interleukin-5 (Interleukin 5)IBA
09/2011
1Bortezomib (Velcade)FDA Link
07/2011
1Peptide Hydrolases (Proteases)FDA Link
01/2011
1AutoantigensIBA
01/2011
1Immunoglobulin E (IgE)IBA
11/2010
1ChemokinesIBA
11/2010
1Leptin ReceptorsIBA
05/2010
1GhrelinIBA
05/2010
1LeptinIBA
05/2010
1N 30IBA
01/2010
1Peptides (Polypeptides)IBA
03/2009
1Sulfamethoxazole Drug Combination Trimethoprim (Co-Trimoxazole)FDA LinkGeneric
01/2009
1Oxaliplatin (Eloxatin)FDA LinkGeneric
12/2007
1complement 1q receptorIBA
10/2006
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2002
1Interferon-gamma (Interferon, gamma)IBA
05/2002

Therapy/Procedure

5Therapeutics
10/2021 - 01/2009
2Remission Induction
05/2021 - 01/2009
1Chemoprevention
01/2009